Navegando por Palavras-chave "Bone markers"

Agora exibindo 1 - 2 de 2
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Marcadores Bioquímicos da Remodelação Óssea na Prática Clínica
    (Sociedade Brasileira de Endocrinologia e Metabologia, 2002-02-01) Saraiva, Gabriela Luporini [UNIFESP]; Lazaretti-Castro, Marise [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    In physiological circumstances, bone resorption and formation are coupled processes. When, however, one predominates over the other the result is a gain or a loss of bone mass. To study this dynamic process, biochemical bone markers have been developed. Osteocalcin and bone alkaline phosphatase better represent bone formation, while pyridinoline, deoxypyridinoline and collagen type I cross-linking (amino and carboxi-terminal) telopeptides, the bone resorption. In the follow up of osteoporosis treatment, the bone resorption markers are more specific and sensitive than the formation markers. During the treatment of post-menopausal osteoporosis with anti-reabsortive therapy, the rate of fall from basal values of resorption markers at 3 or 6 months are related to the increase on bone mass after long-term treatment. The bone markers have applications in a number of diseases of the skeleton including osteoporosis, and helped to understand the pathophysiological mechanisms of many diseases that affect bone tissue. Although they still need better sensibility and specificity to be strongly recommended in the clinical routine, their use should be encouraged to assess risk of fractures in special cases, to aid treatment decisions, and to monitor treatment.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Vitamin D deficiency in patients with active systemic lupus erythematosus
    (Springer, 2009-03-01) Borba, V. Z. C. [UNIFESP]; Vieira, J. G. H. [UNIFESP]; Kasamatsu, T. [UNIFESP]; Radominski, S. C.; Sato, E. I. [UNIFESP]; Lazaretti-Castro, M. [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Univ Fed Parana
    We investigated the effects of disease activity on bone metabolism in 36 patients with systemic lupus erythematosus (SLE). Changes in bone remodeling were not explained by corticosteroid use. A high prevalence of 25OHD deficiency in SLE patients indicates the need for vitamin D replacement, mainly during high disease activity periods.We investigated the effects of SLE disease activity on bone metabolism, their relation to inflammatory cytokines and vitamin D levels.We performed a cross-sectional analysis of 36 SLE patients classified according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in high activity (group I: 12 patients, mean age 29.6 years) or in minimal activity (group II: 24 patients, mean age 30.0 years), and compared them to normal controls (group III: 26 women, 32.8 years). Serum calcium, phosphorus, parathyroid and sex hormones, bone remodeling markers, interleukin (IL)-6, soluble IL-6 receptor (sIL-6R), IL-1, tumor necrosis factor-alpha (TNF), 25-hydroxivitamin D (25OHD), and 1,25-dihydroxyvitamin D3 were measured, plus bone mineral density.All cytokines were significantly higher in SLE groups; IL-6 could differentiate SLE patients from controls. in group I, 25OHD levels were lower (P < 0.05), which was related to the SLEDAI (R = -0.65, P < 0.001). in multiple regression analysis, the 25OHD level was associated with SLEDAI, osteocalcin and bone-specific alkaline phosphatase. the SLEDAI score was positively correlated with all measured cytokines and especially TNF (R = 0.75, P < 0.001).SLE patients demonstrated changes in bone remodeling strongly related to disease activity. A high prevalence of 25OHD deficiency was observed in SLE patients, indicating the need for vitamin D replacement.